The results of a Phase III randomized clinical trial have shown that when it comes to detecting clinically significant prostate cancer, Magnetic Resonance Imaging (MRI) with targeted biopsies (MRI-TBx ...
Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial Nearly all men with prostate ...
Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...
New findings from the phase III PRIMARY2 trial presented at EAU26 suggest that PSMA PET/CT imaging after inconclusive or reassuring MRI can safely reduce prostate biopsies by about 50 percent without ...
Evaluation of the aggressive variant prostate cancer molecular profile (AVPCm) in CLIA environments.
Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC. IHC and/or stDNA (any evaluable) 15 of 54 (28%) IHC and/or stDNA (both ...
Tribune Content Agency on MSN
What are the symptoms of prostate cancer?
Screening with the prostate-specific antigen test can detect early-stage prostate cancer while it's still asymptomatic. But some men are diagnosed with prostate cancer only after symptoms appear. Marc ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Toronto - (February 4, 2021) The results of a Phase III randomized clinical trial have shown that when it comes to detecting clinically significant prostate cancer, Magnetic Resonance Imaging (MRI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results